Patent Expirations Offering New Opportunities To Japan Generics Industry

The Japanese drug market is very promising globally and its generics market in particular

is offering a huge potential investment area for pharma players. Specially, the patent expirations are adding fuel to fire in the generic drug market of Japan. As per findings of a latest research report by RNCOS, the most prominent and attractive driver for the growth of generics market is patent expiry of drugs and active ingredients in near future. Currently, nearly 40% of pharmaceutical drugs available in Japan are off patent, and hence, generics manufacturers can tap this opportunity. The government too is very eager to reduce cost in view of the fact that the large proportion of the population is heading towards being aged and has asked hospitals to bring in use the generic drugs.

Further, according to a recent report by RNCOS, Japan Generics Market Analysis, drug launches have been robust and the industry has new launches for neurological and behavioral disorders, diabetes, gastrointestinal problems and circulatory disorders. NIH pharmacies and Diagnosis Procedure Combination (DPC)-based hospitals are playing a major role in promoting generics in Japan. The regulatory procedure for the approval of generics in Japan is well laid out and requires stability and bioequivalence tests. Backed by several promising factors, the Japanese generics market has shown positive developments over the past few years and is expected to grow at a CAGR of around 9% during 2012-2014.

The report provides an in-depth research and rational analysis of the current status and expected position of the Japanese generics market. It facilitates forecasts on overall pharmaceutical industry size and generics market for the period 2012-2014. The research evaluates and analyzes the opportunities for generic companies in Japan in terms of patent expiries and therapeutic areas to be tapped. Regulatory environments overview and recent industry developments have also been included in the study to present a balanced outlook of the Japanese generic drugs market to clients. Of particular interest in the report, is the insight given to elucidate consumers attitude towards generics and factors governing decision making by consumers, physicians, and pharmacists.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM371.htm

Some of our Related Reports are:

- Cancer Generics Market Analysis (http://www.rncos.com/Report/IM353.htm)

- Generic Drug Market in Canada (http://www.rncos.com/Report/IM598.htm)

- Booming Generics Drug Market in India (http://www.rncos.com/Report/IM256.htm)

- UK Generics Market Analysis (http://www.rncos.com/Report/IM313.htm)

- Japanese Generic Market Forecast to 2013 (http://www.rncos.com/Report/IM170.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

by: Shushmul Maheshwari

POST COMMENT

Wordpress - How To Install A New Theme In Wordpress 3.0. Rely On New Age, Slimming Bodysuits To Get That Attractive Look Fossil Fuels Renewable Energy Kul Ecoloch Phase 2 : Filled With Daylight Bringing With It An Optimistic Energy Amazon Has Effectively Used New Era Hats Cheap Price Discounting Many Mind-blowing Treasures Await Your Presence In New Zealand Rental Apartments In New Port Richey Offer Peace & Comfort Hcg Diet Clinics Keep You Healthy, Wealthy, And Full Of Energy! Real Estate In Jaipur: A New Land Of Investments For The Builders Self Storage In New York City Product Design Research Tools For Your New Products Perfect Corporate Gift Ideas For New Year 2013 Discount Coupons- Shopping Has The New High Tech Face.